QCM
SMMT icon

Quantinno Capital Management’s Summit Therapeutics SMMT Stock Holding History

Quantinno Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Buy
113,452
+39,617
+54% +$703K ﹤0.01% 2136
2026
Q1 		$1.4M Buy
73,835
+59,512
+415% +$962K ﹤0.01% 1892
2025
Q4 		$251K Buy
+14,323
New +$269K ﹤0.01% 2940

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Quantinno Capital Management's SMMT Position: Q2 2026 in Review

Quantinno Capital Management increased its Summit Therapeutics (SMMT) stake by 54% in Q2 2026, buying an estimated $703K and bringing the position to 113,452 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2136.

Quantinno Capital Management first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Quantinno Capital Management held 113,452 shares of Summit Therapeutics worth $1.65M as of Q2 2026.
  • Quantinno Capital Management bought 39,617 Summit Therapeutics shares in Q2 2026, an estimated $703K.
  • Summit Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2136 holding.
  • Quantinno Capital Management first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.